ExpertiseUpdated on 25 February 2026
Oxeltis _ Bridge the gap between biology and chemical matter...
About
We address this by:
Seamless integration of in silico design (CADD, SBDD, LBDD, AI/ML) in partnership with Molecular Forecaster (Montreal) and Assay development/in vitro biological screening in partnership with Partex.AI Labs
Rapid hit-to-lead and lead optimization, with a track record of delivering high-quality compounds efficiently and a highly skill team of chemists (50% Ph.D., 50% M.Sc.)
Expertise in complex and enabling chemistries, supported by our hybrid SFC platform for rapid purification and scale-up (up to 25g/day) of chiral/achiral mixtures.
Oxeltis, France-based CRO specialized in medicinal and fine organic chemistry can support early small molecule drug disocvery programs to mature at Hit to Lead and Lead optimization stage.
Field
- Biotech, Pharma and Cosmetics
Organisation
Similar opportunities
Project cooperation
Industrial & Research Partners for Seasonal Low-Cycle Battery Storage Integrated with Photovoltaics
- Early
- Energy
- Research
- Technical
- EU projects
- Nano and Microtechnologies
- Partner looking for consortium
- Coordinator looking for partners
Manfred Baumgärtner
CEO at Whiterock AG
Stuttgart, Germany
Project cooperation
- Research
- Technical
- EU projects
- Nano and Microtechnologies
- Coordinator looking for partners
- Materials, Textiles and Chemicals
- Industrial Equipment and Machinery
- Automotive, Transport and Logistics
Jaromír Ficek
Business Development Manager at VÚTS, a.s.
Liberec, Czech Republic
Project cooperation
EU work packages to accelerate Phase I readiness
- Execution
- Technical
- Biotech, Pharma and Cosmetics
Ramtin Rahbar
Co-founder and Chief Technical Officer at Ness Therapeutics
Toronto, Canada